MetaVia (MTVA) Non-Current Assets (2015 - 2026)
MetaVia's (MTVA) quarterly Non-Current Assets came in at $248000.0 in Q4 2025, up 31.91% YoY from $188000.0 in Q4 2024, and up 108.4% on a QoQ basis from $119000.0 in Q3 2025.
MetaVia (MTVA) Non-Current Assets (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Non-Current Assets data on file, last reported at $248000.0 in Q4 2025.
- Quarterly Non-Current Assets rose 31.91% year-over-year to $248000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $677000.0 (down 23.68% YoY) and the FY2025 annual result came in at $248000.0, up 31.91% from the prior year.
- Non-Current Assets rose to $248000.0 in Q4 2025, from $119000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $280000.0 in Q3 2023 to a low of $2000.0 in Q4 2022.
- A 5-year average of $164750.0 and a median of $204000.0 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 99.07% — and 2023, when it soared 13350.0%.
- Tracing MTVA's Non-Current Assets over 5 years: stood at $215000.0 in 2021, then tumbled by 99.07% to $2000.0 in 2022, then soared by 13350.0% to $269000.0 in 2023, then slumped by 30.11% to $188000.0 in 2024, then soared by 31.91% to $248000.0 in 2025.
- The last three Non-Current Assets figures came in at $248000.0 (Q4 2025), $119000.0 (Q3 2025), and $144000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 204,000.00 |
| Dec 31, 2025 | 248,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 144,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 188,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 234,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 269,000.00 |
| Sep 30, 2023 | 280,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | 2,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Dec 31, 2021 | 215,000.00 |
| Sep 30, 2021 | 233,000.00 |
| Jun 30, 2021 | 251,000.00 |